Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation and Depletion (2016 - 2025)

ImmunityBio (IBRX) has disclosed Depreciation and Depletion for 10 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 8.33% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Dec 2025, down 12.99% year-over-year, with the annual reading at $13.4 million for FY2025, 13.55% down from the prior year.
  • Depreciation and Depletion for Q4 2025 was $3.3 million at ImmunityBio, down from $3.4 million in the prior quarter.
  • The five-year high for Depreciation and Depletion was $4.6 million in Q4 2022, with the low at $3.3 million in Q1 2025.
  • Average Depreciation and Depletion over 5 years is $3.8 million, with a median of $3.9 million recorded in 2022.
  • Peak annual rise in Depreciation and Depletion hit 73.91% in 2021, while the deepest fall reached 37.93% in 2021.
  • Over 5 years, Depreciation and Depletion stood at $3.6 million in 2021, then rose by 27.78% to $4.6 million in 2022, then decreased by 10.87% to $4.1 million in 2023, then decreased by 12.2% to $3.6 million in 2024, then dropped by 8.33% to $3.3 million in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $3.3 million, $3.4 million, and $3.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.